{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T02:22:42Z","timestamp":1781835762083,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Backbone Talent Training Program of the Safeguard Project, Guang\u2019anmen Hospital","award":["9323036"],"award-info":[{"award-number":["9323036"]}]},{"name":"the Beijing Natural Science Foundation","award":["7252259"],"award-info":[{"award-number":["7252259"]}]},{"name":"the High-Level Chinese Medical Hospital Promotion Project","award":["HLCMHPP2023039"],"award-info":[{"award-number":["HLCMHPP2023039"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81973675"],"award-info":[{"award-number":["81973675"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04614-1","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T15:22:22Z","timestamp":1765898542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dioscin attenuates Gd-IgA1 overproduction by inhibiting the IL-6-JAK2\/STAT3 signaling axis in IgA nephropathy"],"prefix":"10.1186","volume":"26","author":[{"given":"Lan","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HuiMei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShiQiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LiHua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShiPeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"issue":"4","key":"4614_CR1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2215\/CJN.07420716","volume":"12","author":"JC Rodrigues","year":"2017","unstructured":"Rodrigues JC, Haas M, Reich HN. IgA nephropathy. Clin J Am Soc Nephrol. 2017;12(4):677\u201386.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"4614_CR2","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/ndt\/gfq665","volume":"26","author":"A McGrogan","year":"2011","unstructured":"McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transpl. 2011;26(2):414\u201330.","journal-title":"Nephrol Dial Transpl"},{"issue":"10","key":"4614_CR3","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1093\/ndt\/gfad082","volume":"38","author":"CJ Willey","year":"2023","unstructured":"Willey CJ, Coppo R, Schaefer F, et al. The incidence and prevalence of IgA nephropathy in Europe. Nephrol Dial Transpl. 2023;38(10):2340\u20139.","journal-title":"Nephrol Dial Transpl"},{"issue":"Suppl 2","key":"4614_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/nep.14343","volume":"29","author":"ISD Roberts","year":"2024","unstructured":"Roberts ISD. Pathology of IgA nephropathy: A global perspective. Nephrol (Carlton). 2024;29(Suppl 2):71\u20134.","journal-title":"Nephrol (Carlton)"},{"issue":"4","key":"4614_CR5","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.kint.2025.01.014","volume":"107","author":"J Floege","year":"2025","unstructured":"Floege J, Bernier-Jean A, Barratt J, et al. Treatment of patients with IgA nephropathy: a call for a new paradigm. Kidney Int. 2025;107(4):640\u201351.","journal-title":"Kidney Int"},{"key":"4614_CR6","doi-asserted-by":"crossref","unstructured":"Rodrigo E, Belmar L, P\u00e9rez-Canga JL. Recurrence of glomerular diseases after kidney transplantation: what do we know new?. Nephron. 2025:1\u201312.","DOI":"10.1159\/000543268"},{"issue":"12","key":"4614_CR7","doi-asserted-by":"publisher","first-page":"eadd6734","DOI":"10.1126\/sciadv.add6734","volume":"9","author":"Y Nihei","year":"2023","unstructured":"Nihei Y, Haniuda K, Higashiyama M, et al. Identification of IgA autoantibodies targeting mesangial cells redefines the pathogenesis of IgA nephropathy. Sci Adv. 2023;9(12):eadd6734.","journal-title":"Sci Adv"},{"issue":"1","key":"4614_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","volume":"21","author":"CK Cheung","year":"2025","unstructured":"Cheung CK, Alexander S, Reich HN, et al. The pathogenesis of IgA nephropathy and implications for treatment. Nat Rev Nephrol. 2025;21(1):9\u201323.","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"4614_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nrneph.2015.208","volume":"12","author":"J Floege","year":"2016","unstructured":"Floege J, Feehally J. The mucosa-kidney axis in IgA nephropathy. Nat Rev Nephrol. 2016;12(3):147\u201356.","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"4614_CR10","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00281-021-00871-y","volume":"43","author":"L Gesualdo","year":"2021","unstructured":"Gesualdo L, Di Leo V, Coppo R. The mucosal immune system and IgA nephropathy. Semin Immunopathol. 2021;43(5):657\u201368.","journal-title":"Semin Immunopathol"},{"issue":"11","key":"4614_CR11","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/ng.3118","volume":"46","author":"K Kiryluk","year":"2014","unstructured":"Kiryluk K, Li Y, Scolari F, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014;46(11):1187\u201396.","journal-title":"Nat Genet"},{"issue":"7","key":"4614_CR12","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/s41588-023-01422-x","volume":"55","author":"K Kiryluk","year":"2023","unstructured":"Kiryluk K, Sanchez-Rodriguez E, Zhou XJ, et al. Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy. Nat Genet. 2023;55(7):1091\u2013105.","journal-title":"Nat Genet"},{"issue":"03","key":"4614_CR13","first-page":"309","volume":"44","author":"TZ Cheng","year":"2024","unstructured":"Cheng TZ, Ren Y, Du YT, et al. Cross-Sectional study on the correlation between traditional Chinese medicine syndromes and mucosal immunity in IgA nephropathy. Chin J Integr Tradit West Med. 2024;44(03):309\u201315.","journal-title":"Chin J Integr Tradit West Med"},{"key":"4614_CR14","doi-asserted-by":"publisher","first-page":"109130","DOI":"10.1016\/j.intimp.2022.109130","volume":"111","author":"M Aliyu","year":"2022","unstructured":"Aliyu M, Zohora FT, Anka AU, et al. Interleukin-6 cytokine: an overview of the immune regulation, immune dysregulation, and therapeutic approach. Int Immunopharmacol. 2022;111:109130.","journal-title":"Int Immunopharmacol"},{"key":"4614_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2022.04.001","volume":"66","author":"Y Groza","year":"2022","unstructured":"Groza Y, Jemelkova J, Kafkova LR, et al. IL-6 and its role in IgA nephropathy development. Cytokine Growth Factor Rev. 2022;66:1\u201314.","journal-title":"Cytokine Growth Factor Rev"},{"key":"4614_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","volume":"66","author":"JJ O\u2019Shea","year":"2015","unstructured":"O\u2019Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311\u201328.","journal-title":"Annu Rev Med"},{"issue":"4","key":"4614_CR17","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/ni.3691","volume":"18","author":"AV Villarino","year":"2017","unstructured":"Villarino AV, Kanno Y, O\u2019Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18(4):374\u201384.","journal-title":"Nat Immunol"},{"issue":"6","key":"4614_CR18","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.ekir.2017.07.002","volume":"2","author":"K Yamada","year":"2017","unstructured":"Yamada K, Huang ZQ, Raska M, et al. Inhibition of STAT3 signaling reduces IgA1 autoantigen production in IgA nephropathy. Kidney Int Rep. 2017;2(6):1194\u2013207.","journal-title":"Kidney Int Rep"},{"issue":"7","key":"4614_CR19","doi-asserted-by":"publisher","first-page":"973","DOI":"10.2215\/CJN.11010919","volume":"15","author":"J Tao","year":"2020","unstructured":"Tao J, Mariani L, Eddy S, et al. JAK-STAT activity in peripheral blood cells and kidney tissue in IgA nephropathy. Clin J Am Soc Nephrol. 2020;15(7):973\u201382.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"07","key":"4614_CR20","first-page":"791","volume":"39","author":"MY Dong","year":"2019","unstructured":"Dong MY, Ding TT, Rao XR, et al. A propensity Score-Matched study on the efficacy of Yiqi Qingjie formula combined with immunosuppressants in the treatment of High-Risk IgA nephropathy. Chin J Integr Tradit West Med. 2019;39(07):791\u20137.","journal-title":"Chin J Integr Tradit West Med"},{"issue":"12","key":"4614_CR21","first-page":"2246","volume":"16","author":"JC Shen","year":"2021","unstructured":"Shen JC, Ren Y, Rao XR, et al. Exploring the molecular mechanism of Dioscorea Nipponica Makion in the treatment of IgA nephropathy based on network Pharmacology, molecular Docking, and in vitro experiments. World J Integr Tradit West Med. 2021;16(12):2246\u201354.","journal-title":"World J Integr Tradit West Med"},{"key":"4614_CR22","doi-asserted-by":"crossref","unstructured":"Lin L, Shen J, Wu X et al. Dioscin mediated IgA nephropathy alleviation by inhibiting B cell activation in vivo and decreasing galactose-deficient IgA1 production in vitro. J Vis Exp. 2023;(200).","DOI":"10.3791\/65719"},{"issue":"8","key":"4614_CR23","doi-asserted-by":"publisher","first-page":"906","DOI":"10.4103\/0366-6999.204101","volume":"130","author":"JN Zou","year":"2017","unstructured":"Zou JN, Xiao J, Hu SS, et al. Toll-like receptor 4 signaling pathway in the protective effect of Pioglitazone on experimental Immunoglobulin A nephropathy. Chin Med J (Engl). 2017;130(8):906\u201313.","journal-title":"Chin Med J (Engl)"},{"key":"4614_CR24","unstructured":"Xu SY, Bian RL, Chen X. Pharmacological experimental methodology, 2nd Edition. Chin. Pharmacol. 1992; 2(01):19."},{"issue":"93","key":"4614_CR25","doi-asserted-by":"publisher","first-page":"eadj7363","DOI":"10.1126\/sciimmunol.adj7363","volume":"9","author":"M De Giovanni","year":"2024","unstructured":"De Giovanni M, Vykunta VS, Biram A, et al. Mast cells help organize the peyer\u2019s patch niche for induction of IgA responses. Sci Immunol. 2024;9(93):eadj7363.","journal-title":"Sci Immunol"},{"issue":"5","key":"4614_CR26","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1681\/ASN.2021081086","volume":"33","author":"K Zachova","year":"2022","unstructured":"Zachova K, Jemelkova J, Kosztyu P, et al. Galactose-Deficient IgA1 B cells in the circulation of IgA nephropathy patients carry preferentially lambda light chains and mucosal homing receptors. J Am Soc Nephrol. 2022;33(5):908\u201317.","journal-title":"J Am Soc Nephrol"},{"issue":"25","key":"4614_CR27","doi-asserted-by":"publisher","first-page":"11462","DOI":"10.7150\/thno.49778","volume":"10","author":"JW He","year":"2020","unstructured":"He JW, Zhou XJ, Lv JC, et al. Perspectives on how mucosal immune responses, infections and gut Microbiome shape IgA nephropathy and future therapies. Theranostics. 2020;10(25):11462\u201378.","journal-title":"Theranostics"},{"issue":"3","key":"4614_CR28","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1159\/000505748","volume":"6","author":"K Yamada","year":"2020","unstructured":"Yamada K, Huang ZQ, Raska M, et al. Leukemia inhibitory factor signaling enhances production of Galactose-Deficient IgA1 in IgA nephropathy. Kidney Dis (Basel). 2020;6(3):168\u201380.","journal-title":"Kidney Dis (Basel)"},{"issue":"12","key":"4614_CR29","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/ki.2012.192","volume":"82","author":"H Tamouza","year":"2012","unstructured":"Tamouza H, Chemouny JM, Raskova Kafkova L, et al. The IgA1 immune complex-mediated activation of the MAPK\/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy. Kidney Int. 2012;82(12):1284\u201396.","journal-title":"Kidney Int"},{"issue":"2","key":"4614_CR30","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.kint.2019.08.022","volume":"97","author":"Y Makita","year":"2020","unstructured":"Makita Y, Suzuki H, Kano T, et al. TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy. Kidney Int. 2020;97(2):340\u20139.","journal-title":"Kidney Int"},{"issue":"3","key":"4614_CR31","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1681\/ASN.2020060823","volume":"32","author":"YN Wang","year":"2021","unstructured":"Wang YN, Zhou XJ, Chen P, et al. Interaction between GALNT12 and C1GALT1 associates with Galactose-Deficient IgA1 and IgA nephropathy. J Am Soc Nephrol. 2021;32(3):545\u201352.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"4614_CR32","doi-asserted-by":"publisher","first-page":"5330","DOI":"10.1074\/jbc.M113.512277","volume":"289","author":"H Suzuki","year":"2014","unstructured":"Suzuki H, Raska M, Yamada K, et al. Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes. J Biol Chem. 2014;289(8):5330\u20139.","journal-title":"J Biol Chem"},{"key":"4614_CR33","doi-asserted-by":"publisher","first-page":"114018","DOI":"10.1016\/j.jep.2021.114018","volume":"274","author":"X Li","year":"2021","unstructured":"Li X, Liu S, Qu L, et al. Dioscin and diosgenin: insights into their potential protective effects in cardiac diseases. J Ethnopharmacol. 2021;274:114018.","journal-title":"J Ethnopharmacol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04614-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04614-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04614-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T03:02:08Z","timestamp":1765940528000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-025-04614-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4614"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04614-1","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"30 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences (protocol code 2023-205-KY and date of 31 October 2023 approval). Since the clinical research involved is an observational study, it is stated that \u201cClinical trial number: not applicable.\u201d The animal study protocol was approved by the Laboratory Animal Centre of Guang\u2019anmen Hospital (protocol code IACUC-GAMH-2023-003 and date of 1 February 2023 approval).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"697"}}